Biodefense/Emerging Infection Vaccine Studies

Ledgerwood, Julie

Abstract

Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. In FY14 this project included clinical assessments and data analysis for clinical trials of investigational vaccines against four types of infectious diseases: filoviruses (Marburg and Ebola), influenza (avian and seasonal strains), alphaviruses (Chikungunya) and malaria. Further evaluation of vaccine approaches will continue as the VRC develops additional candidate vaccine regimens. Published results from clinical trials have included: an Ebola DNA vaccine study (VRC 204) Clin Vaccine Immunol. 2006. 13(11):1267-77; a West Nile virus DNA vaccine study (VRC 302) J Infect Dis. 2007. 196(12):1732-40; a SARS DNA vaccine study (VRC 301) Vaccine. 2008 Nov 25;26(50):6338-43; a second generation West Nile virus DNA vaccine study (VRC 303) J Infect Dis. 2011, May 15;203(10); a second generation Ebola rAd5 vaccine study (VRC 205) Vaccine. 2010 Oct 27; an H5N1 gene based prime, inactivated boost study (VRC 306) Lancet Infect Dis. 2011 Dec;11(12):916-24; an H5 DNA vaccine study and H5 route study (VRC 304 and VRC 305) Clin Vaccine Immunol. 2012 Nov;19(11):1792-7; a follow on H5N1 prime, inactivated boost interval examination study (VRC 310) J Infect Dis. 2013 Aug 1;208(3):413-7, J Infect Dis. 2013 Aug 1;208(3):418-22; a dose-escalation with experimental challenge to evaluate intravenous administration of PfSPZ vaccine trial (VRC 312) Science. 2013 Sep 20;341(6152):1359-65; a VLP vaccine for Chikungunya (VRC 311) Lancet. 2014 Aug 14; an Ebola and Marburg vaccine study (VRC 206) J Infect Dis. In Press.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Investigator-Initiated Intramural Research Projects (ZIA)
• Project #: 1ZIAAI005047-12
• Application #: 8946586
• Support Year: 12
• Fiscal Year: 2014

Institution

• Name: Niaid Extramural Activities

Publications

Yassine, Hadi M; McTamney, Patrick M; Boyington, Jeffery C et al. (2018) Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera. Sci Rep 8:8628

Gaudinski, Martin R; Houser, Katherine V; Morabito, Kaitlyn M et al. (2018) Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391:552-562

Goo, Leslie; DeMaso, Christina R; Pelc, Rebecca S et al. (2018) The Zika virus envelope protein glycan loop regulates virion antigenicity. Virology 515:191-202

Grifoni, Alba; Pham, John; Sidney, John et al. (2017) Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. J Virol :

Ishizuka, Andrew S; Lyke, Kirsten E; DeZure, Adam et al. (2016) Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22:614-23

Dowd, Kimberly A; DeMaso, Christina R; Pelc, Rebecca S et al. (2016) Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Rep 16:1485-1491

Misasi, John; Gilman, Morgan S A; Kanekiyo, Masaru et al. (2016) Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351:1343-6

Corti, Davide; Misasi, John; Mulangu, Sabue et al. (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351:1339-42

Ewer, Katie; Rampling, Tommy; Venkatraman, Navin et al. (2016) A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 374:1635-46

Ngwuta, Joan O; Chen, Man; Modjarrad, Kayvon et al. (2015) Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7:309ra162